Kolon Life Science to ship first supply of ‘Invossa’ to Hong Kong and Macao
Kolon Life Science(CEO Woo-Seok Lee) announced to ship the first supply of the knee arthritis gene therapy ‘INVOSSA-K’ to Hong Kong and Macao.
This shipment is the first supply to Hong Kong and Macao after the agreement with Zhongji 1 International Medical Group on 20 June. The company agreed to...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.